NovoCure Limited

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-17 pm EDT			5-day change	1st Jan Change
17.43 ^USD	-2.65%		+3.14%	-41.51%

Jun. 04	Novocure Insider Sold Shares Worth $528,413, According to a Recent SEC Filing	MT
Jun. 02	NovoCure Limited - Special Call

NovoCure's Q1 Loss Narrows, Revenue Rises

Published on 04/24/2025 at 09:08, updated on 04/24/2025 at 09:16

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about NovoCure Limited

Novocure Insider Sold Shares Worth $528,413, According to a Recent SEC Filing	Jun. 04	MT
NovoCure Limited - Special Call	Jun. 02
Zai Lab and Novocure Announce Results from the Phase 3 Panova-3 Trial of Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 Asco Annual Meeting	May. 31	CI
Novocure Says Ttfields Therapy Shows Significant Improvement In Overall Survival For Pancreatic Cancer	May. 31	RE
Novocure Announces Results from the Phase 3 Panova-3 Trial of Novocure's Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 ASCO Annual Meeting	May. 31	CI
Novocure Announces Upcoming Investor Events	May. 27	RE
NovoCure's Q1 Loss Narrows, Revenue Rises	Apr. 24	MT
NovoCure Limited, Q1 2025 Earnings Call, Apr 24, 2025	Apr. 24
Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $155M, vs. FactSet Est of $146.9M	Apr. 24	MT
Earnings Flash (NVCR) NOVOCURE Posts Q1 Loss $-0.31 Per Share, vs. FactSet Est of $-0.46	Apr. 24	MT
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 24	CI
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of Its Tumor Treating Fields Therapy for Pancreatic Cancer as A Late-Breaking Oral Presentation At the 2025 ASCO Annual Meeting	Apr. 23	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Apr. 22	MT
NovoCure Says Optune Lua Device Gets CE Mark to Treat Lung Cancer	Apr. 22	MT
Novocure'S Optune Lua® Receives CE Mark Approval	Apr. 22	RE
Novocure Insider Sold Shares Worth $266,126, According to a Recent SEC Filing	Mar. 03	MT
Novocure Insider Sold Shares Worth $296,257, According to a Recent SEC Filing	Mar. 03	MT
NovoCure's Q4 Loss Widens, Revenue Rises	Feb. 27	MT
NovoCure Limited, Q4 2024 Earnings Call, Feb 27, 2025	Feb. 27
Earnings Flash (NVCR) NOVOCURE Reports Q4 Revenue $161.3M, vs. FactSet Est of $161.3M	Feb. 27	MT
NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	Feb. 27	CI
NovoCure Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Feb. 27	CI
C Worldwide Healthcare Select up 5.8% in January - divests Illumina	Feb. 12	FW
NovoCure Opens New Global Headquarters in Switzerland	Jan. 22	MT
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland	Jan. 22	CI

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Employees

1,488

Sector

Medical Equipment, Supplies & Distribution

Calendar

Jul. 23 - Q2 2025 Earnings Release (Projected)

More about the company